New path to healing
ABOUT SPRAVATO®
SPRAVATO® is an FDA-approved esketamine nasal spray designed for adults facing treatment-resistant depression or major depressive disorder (MDD) with suicidal thoughts or behaviors. As a specialized form of ketamine, it delivers a rapid-acting alternative for those who haven’t responded to conventional antidepressants.
Since its FDA approval in 2019, SPRAVATO® has offered new hope to individuals struggling to find relief through traditional depression treatments.
Innovative Care for Treatment-Resistant Depression.
SPRAVATO® Treatment Phases
-
Phase One
Week 1-2
Two treatments each week
-
Phase Two
Week 5-8
1 treatment each week
-
Phase Three
Week 9+
One treatment every 1 -2 weeks
